The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

whnfskj.com

Stage

Series C | Alive

Total Raised

$145.38M

Last Raised

$62.64M | 7 mos ago

About Neurophth

Neurophth specializes in the development of ophthalmic gene drugs for eye genetic diseases.

Neurophth Headquarter Location

C270-C271, 3rd Floor, Building B1, Optics Valley Biological City, No. 666 Gaoxin Avenue East Lake New Technology Development Zone

Wuhan, Hubei,

China

+86 027-65524119

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Neurophth

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neurophth is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Neurophth News

09:00 EDT Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer

Jun 2, 2022

News provided by Share this article Share this article SHANGHAI and SAN DIEGO, June 2, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced the appointment of Xiaoning Guo, Ph.D., as the Chief Medical Officer (CMO). Dr. Xiaoning Guo will have overall responsibility for the drug development function, including clinical development, medical, and pipeline management. Dr. Guo has over 20 years of experiences in drug discovery and development in the healthcare industry, including 10 years' clinical development and portfolio management experiences in R&D in multinational pharmaceutical companies and global CRO. He joins Neurophth from SciClone Pharmaceuticals, where he served as Head of R&D and Chief Medical Officer, leading the development of several drugs and clinical work. Prior to joining SciClone Pharmaceuticals, he was the deputy general manager, the head of clinical development and regulatory affairs at General Regeneratives (Shanghai) Limited. He held key leadership positions in drug discovery and development at AstraZeneca, Johnson & Johnson, Covance, leading multiple global R&D projects. Dr. Guo received his PhD in Pharmacology from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and his BSc in Chemistry from Nanjing University. He is also a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), Chinese Society of Clinical Oncology (CSCO) and Chinese Pharmacological Society (CPS). "I'm delighted to welcome Dr. Guo on behalf of the whole company." said Prof. Bin Li, Founder, Chairman and CEO at Neurophth, "The IND application of our core product NR082 has been approved by both NMPA and FDA, and we poised to carry out phase III clinical trial in China and phase I in US. At this critical juncture, Dr. Guo will make a great addition to Neurophth executive team, bringing his profound global clinical experiences, deep medical expertise, and outstanding leadership. We look forward to his partnership in enhancing our capabilities and efficiency in clinical development, optimizing our pipeline strategy, and staging the new initiatives in our strategic development." Dr. Guo, Chief Medical Officer suggested that "Neurophth has been in the forefront of gene therapy for ocular disease. I shared the same vision of making meaningful changes through innovative gene therapy and I'm looking forward to joining the endeavor with the whole team in accelerating the global clinical development of gene therapy, delivering on our commitment, and contributing to our goal of becoming the world's leading gene therapy company." About Neurophth Neurophth is China's leading in-vivo gene therapy company for ophthalmic diseases. With subsidiaries in China (Wuhan, Shanghai, and Suzhou) and US (San Diego, California), Neurophth, a fully integrated company, is striving to discover and develop genomic medicines for patients suffering from genetic diseases globally. Our validated AAV platform, which has been published in Nature - Scientific Reports, Ophthalmology, and EBioMedicine, has successfully delivered proof-of-concept investigator-initiated trials data of 186 subjects with investigational gene therapies in the retina. Our most advanced investigational gene therapy drug candidate, NR082 (rAAV2-ND4), in development for the treatment of mtND4-mediated LHON, has been granted orphan drug designation (ODD) by the U.S. FDA, an integrated Phase 1/2/3 clinical trial has been initiated with the first patient dosed in June 2021 after the IND clearance by the China NMPA in March 2021, and US IND has recently been cleared by US FDA. The pipeline also includes mtND1-mediated LHON (the Company's 2nd US ODD), autosomal dominant optic atrophy, optic neuroprotection, vascular retinopathy, and five other preclinical candidates. Neurophth has scaled up in-house manufacturing capability in Suzhou facility utilizing single-use technologies to support future commercial demand. To learn more about us and our growing pipeline, visit www.neurophth.com . SOURCE Neurophth Therapeutics, Inc.

  • Where is Neurophth's headquarters?

    Neurophth's headquarters is located at C270-C271, 3rd Floor, Building B1, Optics Valley Biological City, No. 666 Gaoxin Avenue, Wuhan.

  • What is Neurophth's latest funding round?

    Neurophth's latest funding round is Series C.

  • How much did Neurophth raise?

    Neurophth raised a total of $145.38M.

  • Who are the investors of Neurophth?

    Investors of Neurophth include Sequoia Capital China, CMB International Capital, Sunshine Insurance Group, SDIC CMC Investment Management, Northern Light Venture Capital and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.